Amgen reports Q3 2026 earnings: Amgen delivered another strong quarter, reflecting the performance our strategy was designed to achieve. Safe Harbor: $AMGN

AMGEN $AMGN Q3’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $10.37B (Est. $10.07B) 🟢; +8% YoY 🔹 Adj. EPS: $6.45 (Est. $5.79) 🟢; +14% YoY 🔹 Non-GAAP Oper Income: $4.68B (Est. $4.33B) 🟢 FY26 Guide: 🔹 Revenue: $38.9B-$39.7B (Est. $38.94B) 🟡 🔹 Adj. EPS: $22.90-$23.70 (Est. $23.02) 🟡 🔹 GAAP EPS: $18.34-$19.28 🔹 GAAP Tax Rate: 14.5%-16.0% 🔹 Non-GAAP Tax Rate: 15.0%-16.5% 🔹 CapEx: $2.6B 🔹 Share Repurchases: ≤$3.0B Product Sales: 🔹 Repatha: $1.09B (Est. $1.04B) 🟢; +37% YoY 🔹 Evenity: $0.75B (Est. $727M) 🟢; +39% YoY 🔹 Tezspire: $0.54B (Est. $553M) 🔴; +43% YoY 🔹 Prolia: $0.63B (Est. $686M) 🔴; -45% YoY 🔹 Otezla: $0.48B (Est. $510M) 🔴; -18% YoY 🔹 Blincyto: $0.50B (Est. $490.7M) 🟢; +27% YoY 🔹 Enbrel: $0.61B (Est. $485M) 🟢; +5% YoY 🔹 Uplizna: $0.45B (Est. $391M) 🟢; +191% YoY 🔹 Kyprolis: $0.33B (Est. $330.4M) 🟡; -8% YoY 🔹 Xgeva: $0.29B (Est. $324.2M) 🔴; -47% YoY Other Q3 Metrics: 🔹 Total Product Sales: $9.88B; +8% YoY 🔹 Free Cash Flow: $3.7B; -12% YoY 🔹 Non-GAAP Operating Margin: 47.3%; +20 bps YoY Announcements: 🔹 Sales Growth: 17 products delivered at least double-digit sales growth Comments: 🔸 “The strength of our commercial portfolio, combined with important clinical advances and a promising late-stage pipeline, reinforces our confidence in Amgen's ability to deliver durable growth well into the next decade.”

Amgen's best chance at breaking into the high-stakes obesity drug market got its start in a basement at the University of Iceland Science Park in Reykjavík, in a freezer chilled to -13 degrees Fahrenheit. Bloomberg's @g0ingmad explains